{"entity":{"id":"da-target-amyloid-beta","kind":"target","name":"Amyloid-beta","aka":[],"tldr":"Amyloid-beta is the protein fragment that forms plaques in Alzheimer’s disease. Clearing it is the idea behind several antibodies.","summary":"Plaque reduction is now a measurable drug effect. Whether enough clinical benefit follows, for whom, is the practical question.","asOf":"2026-09-21","links":[{"label":"NIA","url":"https://www.nia.nih.gov/health/alzheimers-and-dementia"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":["da-lecanemab","da-donanemab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"APP/Aβ","biology":"Peptides from amyloid precursor protein that aggregate into plaques.","whereFound":["Alzheimer’s disease cortex and vessel walls (CAA)."],"targetClass":"other","prevalence":[]},"route":"/targets/da-target-amyloid-beta/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"drug":[{"id":"da-donanemab","kind":"drug","name":"Donanemab","route":"/drugs/da-donanemab/"},{"id":"da-lecanemab","kind":"drug","name":"Lecanemab","route":"/drugs/da-lecanemab/"},{"id":"da-remternetug","kind":"drug","name":"Remternetug","route":"/drugs/da-remternetug/"}],"pathway":[{"id":"da-pathway-amyloid-tau","kind":"pathway","name":"Amyloid and tau cascade (simplified)","route":"/pathways/da-pathway-amyloid-tau/"}]}}